Nivolumab Demonstrates Durable Response in Refractory Biliary Tract Cancer
The phase II study found that nivolumab was well tolerated and demonstrated moderate efficacy with durable response in patients with refractory biliary tract cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Hannah Slater Source Type: news